Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
XYREM (sodium oxybate) is an oral solution containing the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous GABA metabolite that acts as a CNS depressant. It is indicated for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients aged 7 years and older with narcolepsy. The exact mechanism of action remains unknown, but it is hypothesized to work through GABA-B receptor actions on noradrenergic, dopaminergic, and thalamocortical neurons. XYREM is the market-leading therapy for narcolepsy and has been the standard of care since FDA approval in 2002.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy
Sodium Oxybate in Patients With Chronic Fatigue Syndrome.
Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
Worked on XYREM at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moXYREM supports specialized career opportunities in narcolepsy management, including brand management roles focused on rare disease expertise, medical science liaisons with deep neurological knowledge, and field teams navigating the complex reimbursement landscape for high-cost orphan therapies. Success requires expertise in rare disease awareness, patient advocacy coordination, payer negotiation, and competitive response to emerging extended-release formulations. Currently zero open positions are linked to XYREM, reflecting the product's mature, stable commercial stage without active expansion initiatives.